Alan Miranda

Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins

Oliviero Cini, Alan Miranda, Daan Willocx, Angeliki Karakasidi et autres

Abstract Background Cysteine cathepsin L (CatL) is emerging as a key biomarker of cancer progression, making it an attractive candidate for non-invasive molecular imaging. To monitor enzymatic activity directly, rather than merely protein expression, activity-based probes (ABPs) enable selective targeting of enzymes …

pt, be, de (code pays fourni par la source)

Additional file 1 of Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins

Oliviero Cini, Alan Miranda, Daan Willocx, Angeliki Karakasidi et autres

Supplementary Material 1

pt, be, de (code pays fourni par la source)

Additional file 1 of Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins

Oliviero Cini, Alan Miranda, Daan Willocx, Angeliki Karakasidi et autres

Supplementary Material 1

pt, be, de (code pays fourni par la source)

Additional file 1 of Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins

Oliviero Cini, Alan Miranda, Daan Willocx, Angeliki Karakasidi et autres

Supplementary Material 1

pt, be, de (code pays fourni par la source)

Accurate Reference Region Calculation in Mouse Brain [18F]fallypride Studies

Alan Miranda, Filipe Elvas, Steven G. Staelens

be (code pays fourni par la source)

Comparing kinetic profiles of SV2A radiotracers [ 18 F]SynVesT-1 and [ 18 F]UCB-J using PET imaging in mice

Liesbeth Everix, Alan Miranda, Jordy Akkermans, Vinod K. Khetarpal et autres

Deficits in the synaptic vesicle protein 2A (SV2A) have been reported in various neurodegenerative diseases including Alzheimer’s and Huntington’s disease (HD). SV2A levels can be investigated using positron emission tomography (PET) radioligands such as [ 11 C]UCB-J, [ 18 F]UCB-J, and [ …

be, us (code pays fourni par la source)

Abstract 5822: Efficacy of targeted radionuclide therapy Using 131I-FAPi dimers labeled via tetrazine ligation in a human glioblastoma xenograft model

Umberto Maria Battisti, Marcel Martin, Vladimir Shalgunov, Filipe Elvas et autres

Abstract The successful use of diagnostic radiotracers targeting the pan-tumor marker fibroblast activation protein (FAP) across numerous cancer types is well established; however, translating these agents into effective therapeutics remains challenging. Compared with monomeric FAP inhibitors (FAPi), FAPi dimers—containing two FAP-targeting vectors—exhibit …

dk, be (code pays fourni par la source)

SV2A quantification using 18F-SynVesT-1 and 18F-UCB-J PET in 17M heterozygous zQ175DN mice and wild-type littermates (intra-animal tracer comparison).

Liesbeth Everix, Alan Miranda, Jordy Akkermans, Vinod K. Khetarpal et autres

Preclinical evaluation of [11C]CHDI-009R for quantification of mutant huntingtin aggregates

Franziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt, Jeroen A.J. Verhaeghe et autres

Huntington’s disease (HD) is a neurodegenerative disorder caused by an expanded trinucleotide repeat in the huntingtin gene (HTT) that subsequently leads to aggregation of the mutant huntingtin (mHTT) protein. Thus, lowering mHTT is a key therapeutic approach used by several candidate therapeutics …

be, us (code pays fourni par la source)

In Vivo PET Imaging of [ 18 F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease

Franziska Zajicek, Filipe Elvas, Alan Miranda, Jordy Akkermans et autres

Aggregation of mutant huntingtin (mHTT) is a neurologic hallmark of Huntington disease (HD), a neurodegenerative disorder caused by the expansion of a cytosine–adenine–guanine repeat tract in the huntingtin gene (HTT). With a considerable number of candidate therapeutic interventions aimed at lowering mHTT …

be, us (code pays fourni par la source)

Imaging brain development in a KCNQ2-developmental and epileptic encephalopathy mouse model: identifying early biomarkers for functional and structural brain changes

Charissa Millevert, Nicholas Vidas-Guscic, Mohit H. Adhikari, Alan Miranda et autres

BACKGROUND: KCNQ2-developmental and epileptic encephalopathy (KCNQ2-DEE) is a severe neurodevelopmental disorder (NDD) characterised by early-life seizures but persistent cognitive impairment. The absence of early, quantifiable preclinical biomarkers for neurodevelopmental dysfunction limits the evaluation of new treatments. We hypothesise that key brain maturation …

be, fr (code pays fourni par la source)

Synthesis and Preclinical Evaluation of Druglike 18F-Labeled Fibroblast Activation Protein (FAP) Inhibitors with Enhanced Tumor Retention

Karuna Adhikari, Sergei Grintsevich, Anke de Groot, Emile Verhulst et autres

Fibroblast activation protein (FAP) is upregulated in cancer and fibrosis, making it an ideal target for imaging and therapy. Most FAP radioligands are large, highly polar, chelator-based molecules that suffer from limited tissue penetration and rapid tumor washout. In this study, we …

be (code pays fourni par la source)